Study of an Immunotherapeutic, DPX-Survivac, in Combination With Low Dose Cyclophosphamide & Pembrolizumab, in Subjects With Selected Advanced & Recurrent Solid Tumors
Clinical trial NCT03836352 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT03836352
- Sponsor
- ImmunoVaccine Technologies, Inc. (IMV Inc.)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2018-12-21
- Primary completion
- 2023-12-31
- Enrollment
- 184
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.